Publication:
Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies

dc.contributor.authorV. Beralen_US
dc.contributor.authorC. Hermonen_US
dc.contributor.authorR. Petoen_US
dc.contributor.authorG. Reevesen_US
dc.contributor.authorL. Brintonen_US
dc.contributor.authorP. Marchbanksen_US
dc.contributor.authorE. Negrien_US
dc.contributor.authorR. B. Nessen_US
dc.contributor.authorP. H.M. Peetersen_US
dc.contributor.authorM. Vesseyen_US
dc.contributor.authorE. E. Calleen_US
dc.contributor.authorS. M. Gapsturen_US
dc.contributor.authorA. V. Patelen_US
dc.contributor.authorL. Dal Masoen_US
dc.contributor.authorR. Talaminien_US
dc.contributor.authorA. Chetriten_US
dc.contributor.authorG. Hirsh-Yechezkelen_US
dc.contributor.authorF. Lubinen_US
dc.contributor.authorS. Sadetzkien_US
dc.contributor.authorN. Allenen_US
dc.contributor.authorD. Bullen_US
dc.contributor.authorK. Callaghanen_US
dc.contributor.authorB. Crossleyen_US
dc.contributor.authorK. Gaitskellen_US
dc.contributor.authorA. Goodillen_US
dc.contributor.authorJ. Greenen_US
dc.contributor.authorT. Keyen_US
dc.contributor.authorK. Moseren_US
dc.contributor.authorR. Collinsen_US
dc.contributor.authorR. Dollen_US
dc.contributor.authorC. A. Gonzalezen_US
dc.contributor.authorN. Leeen_US
dc.contributor.authorH. W. Oryen_US
dc.contributor.authorH. B. Petersonen_US
dc.contributor.authorP. A. Wingoen_US
dc.contributor.authorN. Martinen_US
dc.contributor.authorT. Pardthaisongen_US
dc.contributor.authorS. Silpisornkosolen_US
dc.contributor.authorC. Theetranonten_US
dc.contributor.authorB. Boosirien_US
dc.contributor.authorS. Chutivongseen_US
dc.contributor.authorP. Jimakornen_US
dc.contributor.authorP. Virutamasenen_US
dc.contributor.authorC. Wongsrichanalaien_US
dc.contributor.authorA. Tjonnelanden_US
dc.contributor.authorL. Titus-Ernstoffen_US
dc.contributor.authorT. Byersen_US
dc.contributor.authorT. Rohanen_US
dc.contributor.authorB. J. Mosgaarden_US
dc.contributor.authorD. Yeatesen_US
dc.contributor.authorJ. L. Freudenheimen_US
dc.contributor.authorJ. Chang-Claudeen_US
dc.contributor.authorR. Kaaksen_US
dc.contributor.authorK. E. Andersonen_US
dc.contributor.authorA. Folsomen_US
dc.contributor.authorM. A. Rossingen_US
dc.contributor.authorD. B. Thomasen_US
dc.contributor.authorN. S. Weissen_US
dc.contributor.authorE. Ribolien_US
dc.contributor.authorF. Clavel-Chapelonen_US
dc.contributor.authorD. Crameren_US
dc.contributor.authorK. Robienen_US
dc.contributor.authorS. S. Tworogeren_US
dc.contributor.authorD. Crameren_US
dc.contributor.authorS. E. Hankinsonen_US
dc.contributor.authorS. S. Tworogeren_US
dc.contributor.authorS. Franceschien_US
dc.contributor.authorC. La Vecchiaen_US
dc.contributor.authorC. Magnussonen_US
dc.contributor.authorT. Rimanen_US
dc.contributor.authorE. Weiderpassen_US
dc.contributor.authorA. Wolken_US
dc.contributor.authorL. J. Schoutenen_US
dc.contributor.authorP. A. Van den Brandten_US
dc.contributor.authorN. Chantarakulen_US
dc.contributor.authorS. Koetsawangen_US
dc.contributor.authorD. Rachawaten_US
dc.contributor.authorD. Pallien_US
dc.contributor.authorA. Blacken_US
dc.contributor.authorA. Berrington de Gonzalezen_US
dc.contributor.authorD. M. Freedmanen_US
dc.contributor.authorP. Hartgeen_US
dc.contributor.authorA. W. Hsingen_US
dc.contributor.authorJ. V. Laceyen_US
dc.contributor.authorR. N. Hooveren_US
dc.contributor.authorC. Schaireren_US
dc.contributor.authorS. Graff-Iversenen_US
dc.contributor.authorR. Selmeren_US
dc.contributor.authorC. J. Bainen_US
dc.contributor.authorA. C. Greenen_US
dc.contributor.authorD. M. Purdieen_US
dc.contributor.authorV. Siskinden_US
dc.contributor.authorP. M. Webben_US
dc.contributor.otherAmerican Cancer Societyen_US
dc.contributor.otherIRCCS Centro Di Riferimento Oncologico Avianoen_US
dc.contributor.otherThe Gertner Instituteen_US
dc.contributor.otherCancer Epidemiology Uniten_US
dc.contributor.otherClinical Trial Service Uniten_US
dc.contributor.otherInstitute Catala Oncologiaen_US
dc.contributor.otherCenters for Disease Control and Preventionen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherInstitute of Cancer Epidemiology - Denmarken_US
dc.contributor.otherGeisel School of Medicine at Dartmouthen_US
dc.contributor.otherColorado School of Public Healthen_US
dc.contributor.otherAlbert Einstein College of Medicine of Yeshiva Universityen_US
dc.contributor.otherAmtssygehuset i Herleven_US
dc.contributor.otherDepartment of Public Healthen_US
dc.contributor.otherUniversity at Buffalo, State University of New Yorken_US
dc.contributor.otherGerman Cancer Research Centeren_US
dc.contributor.otherUniversity of Minnesota School of Public Healthen_US
dc.contributor.otherUniversity of Washington, Seattleen_US
dc.contributor.otherImperial College Londonen_US
dc.contributor.otherCentre de recherche en epidemiologie et sante des populationsen_US
dc.contributor.otherHarvard Medical Schoolen_US
dc.contributor.otherBrigham and Women's Hospitalen_US
dc.contributor.otherChanning Laboratoryen_US
dc.contributor.otherInternational Agency for Research on Canceren_US
dc.contributor.otherUniversita degli Studi di Milanoen_US
dc.contributor.otherKarolinska Instituteten_US
dc.contributor.otherMaastricht Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherCentro Per Lo Studio E La Prevenzione Oncologicaen_US
dc.contributor.otherNational Cancer Instituteen_US
dc.contributor.otherNorwegian Institute of Public Healthen_US
dc.contributor.otherQueensland Institute of Medical Researchen_US
dc.contributor.otherRoswell Park Cancer Instituteen_US
dc.contributor.otherRoyal College of General Practitioners' Oral Contraception Studyen_US
dc.contributor.otherCurtin Universityen_US
dc.contributor.otherUniversity of Texas Systemen_US
dc.contributor.otherUniversity of Massachusetts Systemen_US
dc.contributor.otherBoston Universityen_US
dc.contributor.otherStanford Universityen_US
dc.contributor.otherUniversity of Athens Medical Schoolen_US
dc.contributor.otherUniversidad de Chileen_US
dc.contributor.otherUniversity of Hawaii Systemen_US
dc.contributor.otherSkånes universitetssjukhusen_US
dc.contributor.otherUniversity of Pennsylvaniaen_US
dc.contributor.otherUniversity Medical Center Utrechten_US
dc.contributor.otherUniversity of Southern Californiaen_US
dc.contributor.otherUniversity of Torontoen_US
dc.contributor.otherUniversitetet i Tromsoen_US
dc.contributor.otherGeorge Washington Universityen_US
dc.contributor.otherVanderbilt Universityen_US
dc.contributor.otherOrganisation Mondiale de la Santeen_US
dc.contributor.otherYale Universityen_US
dc.date.accessioned2018-06-11T05:14:09Z
dc.date.available2018-06-11T05:14:09Z
dc.date.issued2012-04-01en_US
dc.description.abstractBackground: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p < 0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p < 0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m 2 increase in body mass index was 1.10 (95% CI, 1.07-1.13; p < 0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade. © 2012 Collaborative Group on Epidemiological Studies of Ovarian Cancer.en_US
dc.identifier.citationPLoS Medicine. Vol.9, No.4 (2012)en_US
dc.identifier.doi10.1371/journal.pmed.1001200en_US
dc.identifier.issn15491676en_US
dc.identifier.issn15491277en_US
dc.identifier.other2-s2.0-84860157091en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/14892
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84860157091&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleOvarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studiesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84860157091&origin=inwarden_US

Files

Collections